Status:
COMPLETED
Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients
Lead Sponsor:
Mohammed Alnims
Conditions:
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the clinical and echocardiographic outcome of LCZ696 therapy in HFrEF (NYHA Class II - IV and EF =≤ 40%).patients, in addition to the efficacy of LCZ696 in reducing mortality and rehospita...
Eligibility Criteria
Inclusion
- ≥18 year old.
- Functional class using New York Heart Association (NYHA) classification class II, III or IV %).
- Left ventricular systolic dysfunction using transthoracic echocardiography with EF ≤ 40%.
- Who was already taking ACE inhibitors or ARBs.
Exclusion
- Symptomatic hypotension.
- Systolic blood pressure \<100 mm Hg.
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2.
- History of angioedema.
- Hisotry of unacceptable side effects while on while on treatment with an ACE-inhibitor or ARBs.
Key Trial Info
Start Date :
June 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03816306
Start Date
June 1 2018
End Date
December 1 2019
Last Update
January 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt